Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (Q35554823)

8 August 2017

title

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists (English)

1 reference

8 August 2017

0 references

1 reference

6

Ekbom A

1 reference

8 August 2017

16

Klareskog L

1 reference

8 August 2017

Askling J

1

1 reference

8 August 2017

Fored CM

2

1 reference

8 August 2017

Baecklund E

3

1 reference

8 August 2017

Brandt L

4

1 reference

8 August 2017

Backlin C

5

1 reference

8 August 2017

Sundström C

7

1 reference

8 August 2017

Bertilsson L

8

1 reference

8 August 2017

Cöster L

9

1 reference

8 August 2017

Geborek P

10

1 reference

8 August 2017

Jacobsson LT

11

1 reference

8 August 2017

Lindblad S

12

1 reference

8 August 2017

Lysholm J

13

1 reference

8 August 2017

Rantapää-Dahlqvist S

14

1 reference

8 August 2017

Saxne T

15

1 reference

8 August 2017

Feltelius N

17

1 reference

8 August 2017

language of work or name

English

0 references

publication date

20 April 2005

1 reference

Annals of the Rheumatic Diseases

8 August 2017

published in

1 reference

8 August 2017

volume

64

1 reference

8 August 2017

issue

10

1 reference

8 August 2017

page(s)

1414-1420

1 reference

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Hematologic toxicity of immunosuppressive treatment.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Annual incidence of inflammatory joint diseases in a population based study in southern Sweden

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

The relationship between infliximab treatment and lymphoma in Crohn's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

A population based, case control study of non-Hodgkin's lymphoma in patients with rheumatoid arthritis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Immunodeficiency-associated lymphoproliferative disorders

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Rheumatoid arthritis and the risk of malignancy

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Elevated incidence of hematologic malignancies in patients with Sjögren's syndrome compared with patients with rheumatoid arthritis (Finland).

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Mortality from cancer in patients with rheumatoid arthritis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Cancer morbidity in rheumatoid arthritis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Neoplasms of the immune system in rheumatoid arthritis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1755232

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

15 November 2018

1 reference

12 December 2020

Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland

1 reference

12 December 2020

Incidence of Cancer Among Patients With Rheumatoid Arthritis

1 reference

12 December 2020

Incidence of cancer among men with the Felty syndrome

1 reference

12 December 2020

Rheumatoid arthritis and cancer risk

1 reference

12 December 2020

Lack of certainty on the diagnosis of acute intermittent porphyria: comment on the concise communication by Cohen et al

1 reference

12 December 2020

Risk of malignancy among patients with rheumatic conditions

1 reference

12 December 2020

Identifiers

DOI

10.1136/ARD.2004.033241

1 reference

8 August 2017

1 reference

8 August 2017

1 reference